The b-clamp is the processivity-promoting factor for most of the enzymes in prokaryotic DNA replication; hence, it is a crucial drug target. In the present study, we investigated the b-clamp from Helicobacter pylori, aiming to seek potential drug molecules against this gastric-cancer-causing bacterium. An in silico screening of Food and Drug Administration (FDA) approved drugs against the H. pylori b-clamp, followed by its in vitro inhibition using a surface competition approach, yielded the drug diflunisal as a positive initial hit. Diflunisal inhibits the growth of H. pylori in the micromolar range. We determined the structure of diflunisal in complex with the b-clamp to show that the drug binds at subsite I, which is a protein-protein interaction site. Successful identification of FDA-approved molecules against H. pylori may lead to better and faster drug development.
DNA polymerase III holoenzyme is the crucial enzyme complex in prokaryotic DNA replication, and is made up of three basic components: the core polymerase, b-clamp and c complex. b-clamp functions by both interacting with DNA and binding many proteins. By sliding on DNA, b-clamp helps the DNA polymerase III holoenzyme to move along the nucleic acid and increases its processivity. In addition to DNA polymerase III, b-clamp also interacts with several other essential enzymes [1] and components of the DNA replication machinery [2] , leading to the increased processivity [3] . Several DNA polymerases, in particular pol I [1] , pol II [4, 5] , pol IV [6] and pol V [7] , interact with b-clamp, as do other proteins, such as mismatch repair proteins MutS [1] and MutL, as well as DNA ligase [1] and the DnaA-related protein Had [2] .
All these b-clamp-interacting proteins share a common conserved peptide-binding motif [8] . The binding pocket with which these motifs interact is composed of hydrophobic residues [9] . In Helicobacter pylori, the 'ZXSLF' amino acid sequence (where Z represents any hydrophilic amino acid residue and X represents any small hydrophobic residue) has been reported to bind the Hpb-clamp binding pocket [10] . Numerous structures of b-clamp from various organisms have been determined and they show similar basic architectures [9] . The b-clamp is a homodimer and each monomeric unit consists of three similar domains. The groove between domain II and III is involved in interactions with other proteins and this interaction site may be further divided into two protein-binding subsites, denoted as subsites I and II [8, 9, 11, 12] . All b-clamp binding partners share these interaction subsites. Each b-clamp monomer has one site available for interaction, present on the same face of the dimer [13] .
The b-clamp interacts with many proteins and the conserved nature of these interactions across different bacteria makes it an important drug target. Many inhibitors and drugs that target the b-clamp from Escherichia coli have been identified and have been shown to work bth in vitro and in vivo [14] . b-clamp has also been recently targeted for development of drugs against tuberculosis, and this work has shown success in an animal model [15] . However, despite the similarity between the structures of the b-clamps from these different organisms, as indicated above, other relevant characteristics of the organisms vary, such as membrane architecture, biofilm formation and colonization in the host, etc. Thus, an inhibitor designed against bclamp of one organism may not necessarily be equally effective against the b-clamp of another.
Helicobacter pylori is a Gram-negative bacterium and is the major causative agent of gastric cancer worldwide [16] . A most striking feature of this bacterium is its allelic diversity and genetic variability. It undergoes frequent intraspecific recombination and displays an elevated mutation rate as a result of genetic alterations [17] . In addition, some proteins and their functions are different in H. pylori than in other bacteria. For example, unlike in E. coli, H. pylori shows loading of its helicase without loader protein [18, 19] and a strong interaction between its helicase and primase was also seen [20, 21] .
In a previous study, we identified the region of ligase that binds to b-clamp from H. pylori (Hpbclamp), as well as the region of Hpb-clamp that binds the ligase [10] . In the present study, we exploited this information about the ligase-binding site of Hpbclamp to screen drugs approved by the United States Food and Drug Administration (FDA) using various databases. Out of thousands of molecules, only five were obtained based on their in silico binding affinity (glide scores) and availability. One of these molecules, diflunisal, a FDA-approved molecule used as anti-inflammatory drug, showed inhibition against H. pylori growth, with micromolar IC 50 values.
Materials and methods

Protein overexpression and purification
Hpb-clamp was cloned, expressed and purified as described previously [10] . In brief, the recombinant plasmid for Hpbclamp was transformed into the E. coli BL21 strain. For overexpression, the cells were initially grown at 37°C, then induced with 0.5 mM isopropyl thio-b-D-galactoside when D of 0.6 was reached, followed by an incubation at 30°C for 6 h in a shaker, after which they were harvested at 4500 g for 10 min. The resulting cell pellet was dissolved in a lysis buffer [150 mM NaCl, 30 mM Tris-HCl (pH 7.5), 6 mM b-mercaptoethanol and 0.5% Tween 20] containing 10 mM imidazole. Lysozyme (0.3%) was used to lyse the cells, the product of which was then sonicated. The sonicated soup was centrifuged at 18 000 g for 30 min at 4°C, and the resulting supernatant was collected and passed through a pre-equilibrated nickelnitrilotriacetic acid column. After washing the column with a wash buffer consisting of 30 mM imidazole, 200 mM NaCl, 30 mM Tris-HCl (pH 7.5) and 6 mM bMe, elution was carried out using a solution consisting of 150 mM imidazole, 150 mM NaCl, 30 mM Tris-HCl (pH 7.5), 30 mM arginine and 6 mM bMe. The eluted protein was concentrated using a centricon and injected into a pre-equilibrated HiLoad G200 16/60 column (GE Healthcare, Little Chalfont, UK). The running buffer used contained 150 mM NaCl, 30 mM Tris-HCl (pH7.5), 30 mM arginine and 6 mM bMe. The elution was carried out with a flow rate of 1 mLÁmin
À1
. The eluted fraction was checked on a 12% SDS/PAGE gel. The same buffers and procedure was used to purify HpDNA ligase.
Use of docking to screen inhibitors
Screening of inhibitors of Hpb-clamp was carried out based on the analysis of its binding site for ligase. The groove between domains II and III of Hpb-clamp, which was bound to peptide from ligase [10] [Protein Data Bank (PDB) code: 5FRQ], was targeted for inhibitor screening and this ligasebinding region was used for grid generation. For the purpose of docking, MAESTRO was used, which includes Schrodinger's Protein Preparation Wizard [22] , schrodinger ligprep wizard and glide, with all of them being used for docking. Schrodinger's Protein Preparation Wizard was used to remove water and sulphate molecules and to add hydrogen atoms followed by minimization and optimization for inhibitor screening. A library of molecules was generated that consisted of FDAapproved drugs from several databases, including DrugBank [23] , e-LEA3D [24] , NIH Clinical Collection [25] , the binding database (BindingDB) [26] , Therapeutic target database [27] , Virtual library repository (http://rocce-vm0.ucsd.edu/data/sw/ hosted/virtuallib/), Maybridge HitFinder (www.maybridge. com) and Selleckchem (www.selleckchem.com). The set of FDA-approved drugs consisted of thousands of molecules. Schrodinger's Ligprep Wizard was used to generate up to 34 conformations of each molecule from this library. After preparing the ligand library and protein, docking was carried out using the extra precision module in GLIDE using default options [28] [29] [30] . Initially, molecules were listed according to the docking score. However, we were unable to procure all the molecules. Therefore, we selected five molecules (Table 1) based on their GLIDE rankings, as well as their availability. The molecules procured were: eptifibatide acetate (N6-(ami-
We then attempted to co-crystallize these five drug molecules with the Hpb-clamp. Biophysical and antimicrobial assays were carried out to test their inhibitory activities.
Assessment of the disruption of the Hpb-clampHpDNA ligase interaction by the inhibitor molecules using a surface competition assay
The surface plasmon resonance (SPR) system from Autolab (Blackburn, UK) can be used to directly detect the binding of relatively large molecules, although it cannot easily determine the binding affinity directly from the interaction between small molecules and the target protein.
In the present study, we assessed the disruption of the interaction of Hpb-clamp with HpDNA ligase by small molecules by performing a competitive and qualitative analysis using a surface competition approach. The b-clamp was immobilized onto the SPR sensor surface, and then the high molecular weight DNA ligase was used as the analyte and was passed over the sensor surface, which is already cross-linked with b-clamp. The low molecular weight compounds were also mixed with DNA ligase individually and used as competitive analyte. Throughout this assay, the concentration of DNA ligase was kept constant, whereas the concentration of the competitive analyte was increased in progressive injections. The different concentration of analyte passed over the sensor surface is shown in Fig. 2 . The flow cell labeled as 1 was used as a control surface for background subtraction and, in the flow cell labeled 2, b-clamp was immobilized. The buffer used for SPR was Hepes/NaOH buffer (pH 7.0) with 3 mM EDTA (HBS-EP) along with 0.05% surfactant P20 and 2% dimethyl sulfoxide (DMSO). All of the compounds were dissolved in DMSO and diluted in SPR buffer. To limit the changes in bulk refractive index, the DMSO concentration in buffer was matched with the amount of DMSO in the experimental samples.
Co-crystallization and structure determination of the complex
The co-crystallization was performed using the hanging drop vapor diffusion method. The Hpb-clamp protein from gel filtration chromatography column concentrated to 5 mgÁmL
À1
was mixed with ligand (1 mM) and this mixture was further mixed an equal volume of precipitant solution [0.2 M ammonium citrate, 20% v/v poly(ethylene glycol) MME 550, 6% w/v poly(ethylene glycol) 20 000, 0.01 M MgCl 2 , 0.01 M strontium chloride and 0.1 M Mops/Hepes-Na, pH 7.3] and equilibrated against 1 mL of the same precipitant in 24-well plates. These plates were incubated at 16°C and crystals appeared after 4-5 days. Co-crystal with diflunisal was successfully grown and the crystals diffracted the X-rays to a resolution of 2.28 A. The X-ray diffraction data from these crystals were collected at National institute of Immunology (New Delhi, India). HKL-2000 [31] was used to process and integrate the data. The structure was solved by the molecular replacement method with the native Hpb-clamp structure as the search model, using MOLREP in CCP4 [32] . Further, Refmac5 [33] was used for refinement of the structure. The molecular structure was fitted into the electron density using COOT [34] . Finally, the stereochemistry of the model was evaluated by applying PROCHECK [35] and these values, as well as the refinement statistics, are provided in Table 2 . The complex structure coordinates are deposited with PDB codes: 5G48 (Hpb-clamp complex with diflunisal).
Antimicrobial test
Helicobacter pylori strain and culture conditions Helicobacter pylori strain 26695 was cultured on brain heart infusion (BHI) agar/broth medium containing 8% horse blood serum, 0.4% IsoVitaleX (BD Biosciences, Clontech, Palo Alto, CA, USA) and the antibiotics trimethoprim (5 mgÁmL ) and vancomycin (6 mgÁmL À1 ). The bacterial plates were incubated at 37°C under micro-aerobic conditions (5% O 2 , 10% CO 2 ) for 36 h. The broth cultures were incubated on a shaker operating at 110 rpm at 37°C under micro-aerobic conditions (5% O 2 , 10% CO 2 ).
Anti-Helicobacter pylori susceptibility tests
The Kirby-Bauer disk diffusion susceptibility test was used for primary screening of the susceptibility of H. pylori to drugs [36] . Bacteria from fresh plate cultures were resuspended in BHI broth containing 8% horse blood serum, 0.4% IsoVitaleX and the antibiotics. The turbidity of H. pylori suspension was adjusted to 9 9 10 8 bacteria. This high inoculum of H. pylori was used for the disk diffusion method because of the slow growth of the bacteria. In each case, a volume of 200 lL of the H. pylori suspension was spread evenly on 90 mm BHI agar plates. Different concentrations of FDA-approved drugs were prepared from a stock made of pure powders (Sigma, St Louis, MI, USA). Disks (6 mm) were placed on the surface of the bacterial lawn and inoculated with 10 lL of each drug at respective concentrations or DMSO (control). The discs were dried for an additional 5 min followed by incubation at 37°C under micro-aerophilic conditions for 3-5 days. Values in the parentheses are for the highest resolution shell. R-factor = ∑hkl||F obs | À |F calc ||/∑hkl|F obs |, where F calc and F obs are calculated and observed structure factor amplitudes, respectively. Free-R-factor is the same as R-factor, except that the summation is over the randomly selected 'free' reflections excluded from the refinement.
Minimum inhibitory concentration (MIC)
The MIC of drug was determined by applying the dilution method using brain heart infusion broth medium (2 mL each) supplemented with the above-mentioned components (horse blood serum, IsoVitaleX and antibiotics), in which different concentrations of the drugs were used. Fresh H. pylori suspensions were prepared in BHI broth. For the liquid culture assay, a volume of 20 lL of a 1 : 100 dilution H. pylori suspension in BHI broth was added to each tube (2 mL each) and kept at an initial D 600 of < 0.1. Inoculated tubes containing broth and different concentration of drugs were incubated on a shaker (110 rpm) at 37°C under micro-aerobic condition for 20 h. Then, D 600 measurements were taken and analyzed using PRISM (GraphPad Software Inc., San Diego, CA, USA). D 600 measurements were also taken for the H. pylori suspension without drugs or with kanamycin (positive control) and with/without bacteria. All experiments were performed in triplicate.
Results and Discussion
Screening of FDA-approved drugs
In a previous study [10] , we showed how Hpb-clamp binds to HpDNA ligase using SPR, as well as crystallographic studies. In the present study, we utilized information from the crystal structure of Hpb-clamp bound to the peptide from HpDNA ligase (PDB code: 5FRQ). Residues Thr173, Lys176, Arg177, Leu178, Ile248, Ser345, Pro347, Leu368, Met370, Pro371, Ile372 and Thr373 in the cleft between domains II and III of Hpbclamp were shown to be involved in the interaction with HpDNA ligase (PDB code: 5FRQ). This information helped us to define the most suitable binding site for inhibitors and we screened thousands of FDA-approved drug molecules from various databases against this site. On the basis of docking scores and availability, five of the screened drugs were shortlisted (Table 1 ).
All shortlisted molecules disrupted in vitro binding of HpDNA ligase to the Hpb-clamp
To determine the binding capacity of the various molecules for Hpb-clamp, we performed a qualitative analysis by carrying out a surface competition assay. In typical simple direct binding studies using SPR, the sensogram response increases as the concentration of the analyte is increased. This analysis is generally simple because, upon increasing the concentration of the analyte, the number of analyte molecules that are likely to bind the target (i.e. protein) increases and hence an increase in the response curve should be observed. However, in the present study, the analyte molecules (drugs) were very small (less than 500 Da) and they did not elicit a signal from our Autolab SPR instrument. Therefore, we instead used a competitive approach (surface competition assay) to analyse the binding of small molecules to the Hpb-clamp. The basis of this surface competition assay was the competition between a high molecular weight analyte (DNA ligase) and the small molecular weight analyte (FDAapproved) for binding to the b-clamp (Fig. 1) . In this surface competition approach, the measured response was the sum of the contributions from both of the analytes and there was an inverse relationship between the magnitude of the response obtained and the amount of small molecule analyte in the sample [37] . The small molecule/drug-like molecules were expected to compete with ligase for binding to the clamp. With an increasing concentration of analyte (i.e. the small molecule), the sensogram showed a decreased response (Fig. 2) because the small molecule binding to b-clamp did not show the signal. This relationship occurred because the solution that was injected and passed through the sensogram was a mixture of the small molecule and the protein ligase. Initially, when the concentration of inhibitor was low, the response in the sensogram was high as a result of the high molecular weight ligase dominating the binding to the clamp. The small molecules, being low molecular weight compounds, did not produce a detectable signal on the sensor chip even if they were bound to b-clamp. Therefore, the sensogram response was a result of the binding of ligase on the b-clamp. As the concentration of the small molecule was increased, the response decreased because more b-clamp sites became occupied by these molecules and fewer were occupied by ligase because both the small molecules and the ligase bind to the same site (initially deduced from the docked structure of Hp b-clamp with various inhibitors). All of the shortlisted molecules responded positively to this competitive inhibition. The regular decrease in the sensogram response with increasing small molecule concentration for each type of small molecule was indicative of their inhibitory effects. These results indicated that C1 and C3 showed a better competitive binding than the other molecules.
Elucidation of the binding pattern by cocrystallization studies
Once the inhibition was confirmed by the surface competition assay, we attempted to co-crystallize the shortlisted FDA-approved drug molecules with Hpb-clamp. Out of five molecules, one of them, diflunisal (C3) (PDB code: 5G48) successfully crystallized and the complex structure was determined with the clamp. As described in the Introduction, two subsites, subsites I and II, occupy the protein binding site in b-clamp. The crystal structure of Hpb-clamp in complex with the peptide from HpDNA ligase [10] also shows the binding of the ligase peptide at subsites I and II. In the crystal structure of the Hpb-clamp complexed with ligand, the ligand diflunisal also occupies the same subsite I (Fig. 3) . The inhibitor-interacting residues were found to be the same as those observed to contact HpDNA ligase peptide (Fig. 4) . Diflunisal appears to interact with almost all the residues (Thr173, Thr175, Lys176, Leu178, Pro243, Ile248, Pro347, Leu368, Met369 and Met370) of subsite I that formed contacts with the ligase peptide.
A comparison of the ligand-bound Hpb-clamp structure with the native Hpb-clamp structure showed no significant difference in the positions of the ligandinteracting residues (Fig. 4) , except for Lys176, Ile248 and Met370, which moved slightly compared to native structure to firmly bind the inhibitor. Thr173 of Hpbclamp was also observed to make a hydrogen bond with the inhibitor (Fig. 5) .
Comparison of the docked and co-crystal Hpbclamp structure A superimposition of the Hpb-clamp docked structure on the co-crystal structures did not reveal any significant difference in the locations of the inhibitor molecule or of the residues interacting with the inhibitor between the docked and crystallized form. In all of the docked structure, the inhibitor was found to be present in the same pocket as in the crystal structure (Fig. 6) . The Hpb-clamp residue Lys247 hydrogen bonded with the docked inhibitor diflunisal. By contrast, in the actual crystal structure, Thr173 makes a hydrogen bond with the inhibitor. Otherwise, the interaction between the protein and inhibitor is dominated by hydrophobic contacts. 
Antibacterial activity of Hpb-clamp inhibitors
The disk diffusion method [36] was used to assess the susceptibility of H. pylori strain 26695 to each of the shortlisted (C1-C5) drugs. Drugs C3 (diflunisal) showed significant inhibition of the of H. pylori growth, whereas the other four drugs showed no inhibition of bacterial growth (data not shown) according to the clear inhibition zones observed in BHI agar plates (Fig. 7A) . Our results suggested that the drug might have prevented the growth of H. pylori by inhibiting the function of its b-clamp. Furthermore, the MIC was measured on BHI broth culture of H. pylori as described in the Materials and methods. The drug diflunisal (C3) showed significant antimicrobial activities (Fig. 7B) , with MICs of approximately 84 lM. These results suggest that C3 (difunisal) is effective against H. pylori compared to the other screened molecules. Although all of the above drugs (C1-C5) bound to the Hpb-clamp and showed their inhibitory effects in vitro, only one of them (C3) showed inhibition in antimicrobial assay. This difference may have been a result of differential uptake of the drugs by the pathogen.
Conclusions
The b-clamp slides along DNA in prokaryotes and carries out a function similar to that of proliferating cell nuclear antigen in higher organisms, including humans. In prokaryotes, the rate of cell division is quite high; therefore, a very high accuracy of DNA replication and repair is essential for maintaining replication fidelity. b-clamp acts as a protein-protein interaction hub for most of the processes involved in DNA replication and repair. Therefore, the sliding clamp is especially essential for the reproduction and hence survival of prokaryotes. Drugs that target b-clamp of prokaryotes have the potential to be relatively safe for use in humans and other higher organisms because there is no sequence homology between the b-clamp of prokaryotes and proliferating cell nuclear antigen of higher organisms. Earlier studies on E. coli b-clamp [13, 14, 38] showed other anti-inflammatory drugs and other drug-like molecules binding the same site (subsite I), albeit with low IC 50 values. An effective molecule was reported that also binds the same site in Mycobacterium tuberculosis b-clamp [15] .
The present study has advanced the potential development of drugs targeting b-clamp in H. pylori. Our previous work investigating the b-clamp and ligase peptide complex structure [10] has provided a relatively precise description of the specific region of the b-clamp that should be targeted, namely subsite I, which is involved in protein-protein interactions. Targeting subsite I for in silico screening with FDAapproved drugs results in some molecules with a reasonable docking score. Regarding the co-crystal structure of b-clamp with one molecule, diflunisal, the inhibitor was found to bind subsite I of Hpb-clamp, similar to the docked model.
The drug diflunisal (C3) was found to have inhibitory activities in antimicrobial assay against H. pylori, whereas, in vitro, two out of five drugs effectively inhibited the binding of HpDNA ligase. The FDAapproved drug molecule C3 (diflunisal) showed an IC 50 of approximately 80 lM for H. pylori culture. Interestingly, diflunisal is given for arthritis patients, although it has been reported to have side effects as a stomach irritant [39] . More than 50% world population is infected with H. pylori and most infected individuals do not show clinical symptoms. Any drug that acts on H. pylori would cause acidity and irritation if treated without antacids and proton pump inhibitors [40, 41] . The side effect of diflunisal clearly indicates 2F o À F c map, contoured at 1r,of the FDA-approved drug diflunisal (olive) bound to Hpb-clamp (green) (PDB code: 5G48). The structure of this complex is aligned to the native Hpb-clamp structure (4RKI, orange). Comparison of the inhibitor-contacting residues (stick models) of the complex with corresponding residues in the native structure indicates that K176, M370 and I248 moved majorly upon binding the inhibitor. Fig. 6 . Structural alignment of Hpb-clamp-drug co-complex with the Hpb-clamp-drug docking model. Superimposition of the structure of the drug diflunisal (orange) docked into Hpb-clamp (pink) on the corresponding co-crystal structure (green and cyan for Hpb-clamp and drug, respectively). Although the overall orientations of the docked and crystallized drug relative to the protein were similar, they adopted slightly different rotations about the inter-ring bond.
that this drug is acting on H. pylori. Because this is an FDA-approved drug, it could be taken for clinical trials as part of combination therapy to study its effectiveness with respect to curing infection.
The results of the present study are indicative of the crucial nature of this subsite. The competitive binding studies show that binding of the inhibitor to this subsite was responsible for the loss of the DNA ligase interaction with the b-clamp. The weak intermolecular interactions, such as hydrophobic interactions and hydrogen bonds, contribute significantly and cumulatively, playing a key role in stabilizing ligand at the subsite I and competing with protein-protein interactions. 
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Comparison and analysis of residues interacting with peptide from HpDNA ligase (PDB code: 5FRQ) and drug diflunisal shown in stereo view.
